Xeltis is a European medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery. The company develops bioabsorbable synthetic heart valves and vascular grafts intended to enable for the first time endogenous tissue restoration of healthy valves and vessels. Xeltis’ products are synthetic matrices designed to harness the body’s natural healing response. The matrices have the properties to be bioabsorbed as the new valves and vessels grow. Xeltis’ proprietary technology is based on Nobel Prize-winning science.
Millions of people around the world suffer from congenital heart defects, degenerative heart damage or vascular diseases. Among them are more than 100,000 children who are born each year with severe, life-threatening heart defects that would require the reconstruction of the right ventricular outflow tract (RVOT). Under the current standards of care, surgeons may implant plastic prostheses or animal heart valves to repair the damaged or malformed hearts and vessels. However, these techniques have limited efficacy and are plagued with complications, including the potential for rejection, stenosis, calcification and chronic infection and as a result, these children must undergo multiple dangerous surgeries as they age.
Xeltis’s initial focus is to help making the lives of these children free from repeated surgeries in the future. The first product Xeltis plans to commercialize based on its proprietary technology is a replacement pulmonary valve for children with congenital heart malformations. This product alone has the potential to save health systems hundreds of millions of dollars annually by reducing the risk of repeated procedures and the disease burden on both children and their families.
The company’s technology has potential for broad application across a number of cardiovascular conditions and patient populations, serving as the platform addressing hundreds of thousands of patients every year.